Preference for U.S. Manufacturing Sample Clauses

The "Preference for U.S. Manufacturing" clause establishes a requirement or priority for sourcing goods, materials, or components from manufacturers based in the United States. In practice, this means that when procuring products or entering into contracts, preference must be given to U.S.-made items unless exceptions apply, such as unavailability or excessive cost. This clause is designed to support domestic industry, promote local job creation, and ensure compliance with government or organizational policies favoring American manufacturing.
Preference for U.S. Manufacturing. The Parties agree that an important purpose of the CRADA is to improve U.S. competitiveness so as to provide substantial benefit to the U.S. economy. Thus, any product embodying CRADA inventions, or produced through the use of such inventions, for sale or use in the United States by the Collaborator or any affiliate, or licensee, shall be manufactured substantially in the United States.
View SourceView Similar (7)

Related to Preference for U.S. Manufacturing

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time. (b) The Supplier shall not change any process, material, component, packaging or manufacturing location without the Purchaser’s express prior written approval.

  • Preference for domestically manufactured goods The provisions of paragraphs 2.54 and 2.55 of the Guidelines and Appendix 2 thereto shall apply to goods manufactured in the territory of the Borrower.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Reformulation of Products As of the Effective Date, and continuing thereafter, Products that ▇▇▇▇▇▇▇ directly manufactures, imports, distributes, sells, or offers for sale in California shall either: (a) be Reformulated Products pursuant to § 2.2, below; or (b) be labeled with a clear and reasonable exposure warning pursuant to §§ 2.3 and 2.4, below. For purposes of this Settlement Agreement, a “Reformulated Product” is a Product that is in compliance with the standard set forth in

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.